BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 32293338)

  • 1. INHBA is a prognostic predictor for patients with colon adenocarcinoma.
    Li X; Yu W; Liang C; Xu Y; Zhang M; Ding X; Cai X
    BMC Cancer; 2020 Apr; 20(1):305. PubMed ID: 32293338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a risk prediction model and nomogram for colon adenocarcinoma based on methylation-driven genes.
    Zhu L; Sun H; Tian G; Wang J; Zhou Q; Liu P; Tang X; Shi X; Yang L; Liu G
    Aging (Albany NY); 2021 Jun; 13(12):16600-16619. PubMed ID: 34182539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
    Zheng Y; Wu R; Wang X; Yin C
    Front Public Health; 2022; 10():860381. PubMed ID: 35462848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction and identification of immune genes related to the prognosis of patients with colon adenocarcinoma and its mechanisms.
    Chen S; Cao GD; Wei W; Yida L; Xiaobo H; Lei Y; Ke C; Chen B; Xiong MM
    World J Surg Oncol; 2020 Jun; 18(1):146. PubMed ID: 32600423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prognostic model for patients with colon adenocarcinoma.
    Yin C; Wang W; Cao W; Chen Y; Sun X; He K
    Front Endocrinol (Lausanne); 2023; 14():1133554. PubMed ID: 36923226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
    Jin L; Li C; Liu T; Wang L
    Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma.
    Yang M; He H; Peng T; Lu Y; Yu J
    Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a Nomogram by Integrating Molecular Markers and Tumor-Node-Metastasis Staging System for Predicting the Prognosis of Hepatocellular Carcinoma.
    Huang XT; Chen LH; Huang CS; Li JH; Cai JP; Chen W; Yin XY
    Dig Surg; 2019; 36(5):426-432. PubMed ID: 30481744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of the Expression, Prognostic Value, and Immune Infiltration Activities of GABRD in Colon Adenocarcinoma.
    Huang F; Wang Z; Zhu L; Lin C; Wang JX
    Mediators Inflamm; 2023; 2023():8709458. PubMed ID: 37181811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation and verification of the clinical significance and perspective of natural killer group 2 member D ligands in colon adenocarcinoma.
    Ruan GT; Wang S; Zhu LC; Liao XW; Wang XK; Liao C; Yan L; Xie HL; Gong YZ; Gan JL; Gao F
    Aging (Albany NY); 2021 Apr; 13(9):12565-12586. PubMed ID: 33909599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma.
    Zhao F; Liu Y; Gu X; Zhang B; Song C; Cui B
    J BUON; 2021; 26(4):1252-1259. PubMed ID: 34564978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis.
    Dong S; Ding Z; Zhang H; Chen Q
    Integr Cancer Ther; 2019; 18():1534735419864434. PubMed ID: 31370719
    [No Abstract]   [Full Text] [Related]  

  • 18. Establishing and Validating an Aging-Related Prognostic Four-Gene Signature in Colon Adenocarcinoma.
    Zheng L; Yang Y; Cui X
    Biomed Res Int; 2021; 2021():4682589. PubMed ID: 34790819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low expression of bestrophin-2 is associated with poor prognosis in colon cancer.
    Wang L; Zhu H; Sun W; Liang L; Li H; Han C; Huang W; Zhao B; Peng P; Qin M; Shi L; Mo Y; Huang J
    Gene; 2022 Mar; 813():146117. PubMed ID: 34902511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic values of integrin α subfamily mRNA expression in colon adenocarcinoma.
    Gong YZ; Ruan GT; Liao XW; Wang XK; Liao C; Wang S; Gao F
    Oncol Rep; 2019 Sep; 42(3):923-936. PubMed ID: 31322253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.